Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Mini Review
  • Published:

Mini-Review

Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?

Bone Marrow Transplantation volume 29, pages 183–189 (2002)Cite this article

Abstract

Relapse at sites of prior disease involvement accounts for the majority of treatment failures following high-dose therapy and autologous transplantation for both Hodgkin's disease and non-Hodgkin's lymphoma. Several studies have demonstrated the utility of ‘involved-field’ radiation as a treatment modality in this setting to minimize disease bulk prior to transplants, to reduce relapse rates at sites of prior disease involvement and to improve local control for disease resistant to high-dose therapy. Other studies recommend caution due to potential toxicities including radiation-induced pneumonitis and secondary myelodysplasia. Further investigations are needed to better define the optimal extent, dose and timing of radiation in the setting of transplantation, as well as to identify those subsets of patients likely to be at a higher risk of radiation-induced morbidity.

Bone Marrow Transplantation (2002) 29, 183–189. doi:10.1038/sj.bmt.1703367

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fisher RI, Gaynor ER, Dahlberg S et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma New Engl J Med 1993 328: 1002 1006

    Article  CAS  Google Scholar 

  2. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540 1545

    Article  CAS  Google Scholar 

  3. Vose JM, Zhang MJ, Rowlings PA et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 2001 19: 406 413

    Article  CAS  Google Scholar 

  4. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma New Engl J Med 1987 316: 1493 1498

    Article  CAS  Google Scholar 

  5. Canellos GP, Anderson JR, Propert KJ et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD New Engl J Med 1992 327: 1478 1484

    Article  CAS  Google Scholar 

  6. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure J Clin Oncol 1992 10: 210 218

    Article  CAS  Google Scholar 

  7. Lazarus HM, Loberiza FR Jr, Zhang MJ et al. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR) Bone Marrow Transplant 2001 27: 387 396

    Article  CAS  Google Scholar 

  8. Lazarus HM, Rowlings PA, Zhang MJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 1999 17: 534 545

    Article  CAS  Google Scholar 

  9. Phillips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation Blood 1989 73: 2086 2092

    CAS  PubMed  Google Scholar 

  10. Longo DL, Glatstein E, Duffey PL et al. Treatment of localized aggressive lymphomas with combination chemotherapy followed by involved-field radiation therapy J Clin Oncol 1989 7: 1295 1302

    Article  CAS  Google Scholar 

  11. Glick JH, Kim K, Earle J et al. An ECOG randomized phase III trial of CHOP vs. CHOP + radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma Proc Am Soc ASCO 1995 14: 391: 1221a

    Google Scholar 

  12. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma New Engl J Med 1998 339: 21 26

    Article  CAS  Google Scholar 

  13. Aviles A, Delgado S, Nambo MJ et al. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma Int J Radiat Oncol Biol Phys 1994 30: 799 803

    Article  CAS  Google Scholar 

  14. Haioun C, Lepage E, Gisselbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d'Etude des lymphomes de l'Adulte study J Clin Oncol 2000 18: 3025 3030

    Article  CAS  Google Scholar 

  15. Takvorian T, Canellos GP, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis New Engl J Med 1987 316: 1499 1505

    Article  CAS  Google Scholar 

  16. Rapoport AP, Lifton R, Constine LS et al. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1997 19: 883 890

    Article  CAS  Google Scholar 

  17. Mundt AJ, Williams SF, Hallahan D . High dose chemotherapy and stem cell rescue for aggressive non-Hodgkin's lymphoma: pattern of failure and implications for involved-field radiotherapy Int J Radiat Oncol Biol Phys 1997 39: 617 625

    Article  CAS  Google Scholar 

  18. Kewalramani T, Zelenetz AD, Hedrick EE et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin's lymphoma: an intention-to-treat analysis Blood 2000 96: 2399 2404

    CAS  PubMed  Google Scholar 

  19. Friedberg JW, Neuberg D, Monson E et al. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma Biol Blood Marrow Transplant 2001 7: 446 453

    Article  CAS  Google Scholar 

  20. Poen JC, Hoppe RT, Horning SJ . High-dose therapy and autologous bone marrow transplantation for relapsed/refractory Hodgkin's disease: the impact of involved field radiotherapy on patterns of failure and survival Int J Radiat Oncol Biol Phys 1996 36: 3 12

    Article  CAS  Google Scholar 

  21. Mundt AJ, Sibley G, Williams S et al. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease Int J Radiat Oncol Biol Phys 1995 33: 261 270

    Article  CAS  Google Scholar 

  22. Lancet JE, Rapoport AP, Brasacchio R et al. Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors Bone Marrow Transplant 1998 22: 265 271

    Article  CAS  Google Scholar 

  23. Tsang RW, Gospodarowicz MK, Sutcliffe SB et al. Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group Eur J Cancer 1999 35: 73 78

    Article  CAS  Google Scholar 

  24. Toren A, Nagler R, Nagler A . Involved field radiation post autologous stem cell transplantation in lymphoma patients is associated with major haematological toxicities Med Oncol 1998 15: 113 118

    Article  CAS  Google Scholar 

  25. Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors Blood 2000 95: 1588 1593

    CAS  Google Scholar 

  26. Stone RM, Neuberg D, Soiffer R et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma J Clin Oncol 1994 12: 2535 2542

    Article  CAS  Google Scholar 

  27. Gutierrez-Delgado F, Maloney DG, Press OW et al. Autologous stem cell transplantation for non-Hodgkin's lymphoma: comparison of radiation-based and chemotherapy-only preparative regimens Bone Marrow Transplant 2001 28: 455 461

    Article  CAS  Google Scholar 

  28. Goldenberg DM . The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy Crit Rev Oncol Hematol 2001 39: 195 201

    Article  CAS  Google Scholar 

  29. Press OW, Rasey J . Principles of radioimmunotherapy for hematologists and oncologists Semin Oncol 2000 27: 62 73

    CAS  PubMed  Google Scholar 

  30. Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma J Clin Oncol 1999 17: 3793 3803

    Article  CAS  Google Scholar 

  31. Witzig TE . Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma Cancer Chemother Pharmacol 2001 48: (Suppl. 1) S91 S95

    Article  Google Scholar 

  32. Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience Blood 2000 96: 1259 1266

    CAS  PubMed  Google Scholar 

  33. Vose JM, Wahl RL, Saleh M et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas J Clin Oncol 2000 18: 1316 1323

    Article  CAS  Google Scholar 

  34. Winter JN, Inwards D, Erwin W et al. Phase I trial combining 90Y Zevalin and high-dose BEAM chemotherapy with hematopoietic cell transplant in relapsed or refractory B-cell NHL Blood 2001 98: 677a (Abstr. 2835)

    Google Scholar 

  35. Press OW, Eary JF, Gooley T et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas Blood 2000 96: 2934 2942

    CAS  Google Scholar 

Download references

Author information

Author notes

  1. D Schenkein

    Present address: Millenium Pharmaceuticals, Cambridge, MA, USA

Authors and Affiliations

  1. Department of Medicine, Comprehensive Cancer Center of the University Hospitals of Cleveland/Case Western Reserve University, Cleveland, OH, USA

    P Wadhwa & HM Lazarus

  2. Department of Radiation Therapy, Comprehensive Cancer Center of the University Hospitals of Cleveland/Case Western Reserve University, Cleveland, OH, USA

    DC Shina

  3. New England Medical Center, Boston, MA, USA

    D Schenkein

Authors
  1. P Wadhwa
    View author publications

    Search author on:PubMed Google Scholar

  2. DC Shina
    View author publications

    Search author on:PubMed Google Scholar

  3. D Schenkein
    View author publications

    Search author on:PubMed Google Scholar

  4. HM Lazarus
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wadhwa, P., Shina, D., Schenkein, D. et al. Should involved-field radiation therapy be used as an adjunct to lymphoma autotransplantation?. Bone Marrow Transplant 29, 183–189 (2002). https://doi.org/10.1038/sj.bmt.1703367

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703367

Keywords

This article is cited by

Search

Advanced search

Quick links